Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239628 | 0.99 | POLRMT (0.44) | POLRMTDOT1LLMNAHTTSMN1; SMN2 | |
| SCHEMBL26235261 | 0.94 | POLRMT (0.46) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26235400 | 0.90 | POLRMT (0.47) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26238995 | 0.87 | POLRMT (0.48) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26239660 | 0.87 | POLRMT (0.36) | POLRMTDOT1LLMNAHTTSMN1; SMN2 | |
| SCHEMBL26828450 | 0.87 | POLRMT (0.47) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26831777 | 0.86 | POLRMT (0.47) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26235258 | 0.86 | POLRMT (0.46) | POLRMTDOT1LAHCYSTING1RIPK1 | |
| SCHEMBL26230098 | 0.86 | POLRMT (0.48) | POLRMTDOT1LSTING1RIPK1 | |
| SCHEMBL26230341 | 0.85 | POLRMT (0.49) | POLRMTDOT1LSTING1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | POLRMT 13/4885DOT1L 2954/4885LMNA 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.